<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACRPO</journal-id><journal-title-group><journal-title>Asian Case Reports in Oncology</journal-title></journal-title-group><issn pub-type="epub">2169-8821</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACRPO.2017.64005</article-id><article-id pub-id-type="publisher-id">ACRPO-21846</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACRPO20170400000_54132196.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  原发性肝癌合并脾功能亢进低剂量姑息性放射治疗的临床研究
  Clinical Study of Low Dose Palliative Radiotherapy for Hepatocellular Carcinoma Complicated with Hypersplenism
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>树斌</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>袁</surname><given-names>飞</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>武</surname><given-names>云</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>包头医学院肿瘤防治研究所，内蒙古 包头；包头市中心医院检验科，内蒙古 包头</addr-line></aff><aff id="aff2"><addr-line>null</addr-line></aff><aff id="aff1"><addr-line>内蒙古医科大学附属包头临床学院肿瘤科，内蒙古 包头；包头医学院肿瘤防治研究所，内蒙古 包头；包头市中心医院肿瘤科，内蒙古 包头</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>wangtree2000@163.com(王树)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>23</day><month>08</month><year>2017</year></pub-date><volume>06</volume><issue>04</issue><fpage>26</fpage><lpage>32</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   目的：评价原发性肝癌合并脾功能亢进低剂量姑息性放射治疗的疗效及其临床意义。方法：对我院符合诊断标准的28例原发性肝癌伴脾功能亢进患者三维适形放射治疗，分割剂量2 Gy/次，5次/周，总剂量10~25 Gy，治疗4周中监测白细胞，红细胞，血小板，以及门静脉主干，脾静脉和脾指数等各项指标。结果：28例患者在治疗刚开始1周白细胞、血小板有轻度下降，随后白细胞及血小板开始恢复。放疗前后白细胞、血小板数比较，差异有统计学意义(p &lt; 0.05)。治疗后1周复查白细胞及血小板均有不同程度的下降，治疗第3周白细胞、血小板明显上升，治疗后12周血小板开始有下降趋势。对照红细胞及血红蛋白放疗前后比较，差异无统计学意义(p &gt; 0.05)。治疗后门静脉主干，脾静脉，脾指数均有不同程度缩小，差异有统计学意义(p &lt; 0.05)。结论：原发性肝癌导致的脾功能亢进予低剂量姑息性放射治疗可以使脾脏体积和血供减小，白细胞、血小板上升，有效的缓解患者症状。此方法是一种安全、有效的治疗方式，值得临床推广应用。 Object: To evaluate the efficacy and clinical significance of primary hepatocellular carcinoma with low dose palliative radiotherapy. Methods: A total of 28 cases of primary hepatocellular carcinoma with hypersplenism were performed by three-dimensional conformal radiotherapy in our hospital, with the dividing dose of 2 Gy/time, 5 times/week, and the total dose were 10 - 25 Gy. After four weeks of treatment, white blood cells, red blood cells, platelets, and the main body of the portal vein, the splenic vein and the spleen index were monitored. Results: 28 patients had mild decrease in white blood cells and platelets in the first week of treatment, then the white blood cells and platelets begin to recover. The difference of white blood cells and platelet count was statistically significant before and after radiotherapy (p &lt; 0.05). Both white blood cells and platelets were reduced by 1 week after treatment; white blood cells and platelets increased significantly in the third week; platelets began to decline after 12 weeks of treatment. Compared to the erythrocyte and haemoglobin radiotherapy, the difference was not statistically significant (p &gt; 0.05). After treatment, the main vein of the portal vein, the splenic vein, and the spleen index were all reduced to a different degree, and the difference was statistically significant (p &lt; 0.05). Conclusion: Hypersplenism caused by primary liver cancer is associated with low dose palliative radiotherapy which can reduce the volume and blood supply of the spleen, leads to the leucocyte and platelet increased, and alleviate the symptoms of the patients effectively. This method is a safe and effective treatment and is worthy of clinical application.
    
    
  
 
</p></abstract><kwd-group><kwd>放射治疗，原发性肝癌，脾功能亢进, Radiotherapy</kwd><kwd> Hepatocellular Carcinoma</kwd><kwd> Hypersplenism</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>原发性肝癌合并脾功能亢进低剂量姑息性 放射治疗的临床研究<sup> </sup></title><p>王树斌<sup>1,2,3</sup>，袁飞<sup>2,4*</sup>，武云<sup>1,2,3</sup></p><p><sup>1</sup>内蒙古医科大学附属包头临床学院肿瘤科，内蒙古 包头</p><p><sup>2</sup>包头医学院肿瘤防治研究所，内蒙古 包头</p><p><sup>3</sup>包头市中心医院肿瘤科，内蒙古 包头</p><p><sup>4</sup>包头市中心医院检验科，内蒙古 包头</p><disp-formula id="hanspub.21846-formula41"><graphic xlink:href="http://html.hanspub.org/file/2-2530063x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2017年8月8日；录用日期：2017年8月22日；发布日期：2017年8月28日</p><disp-formula id="hanspub.21846-formula42"><graphic xlink:href="http://html.hanspub.org/file/2-2530063x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：评价原发性肝癌合并脾功能亢进低剂量姑息性放射治疗的疗效及其临床意义。方法：对我院符合诊断标准的28例原发性肝癌伴脾功能亢进患者三维适形放射治疗，分割剂量2 Gy/次，5次/周，总剂量10~25 Gy，治疗4周中监测白细胞，红细胞，血小板，以及门静脉主干，脾静脉和脾指数等各项指标。结果：28例患者在治疗刚开始1周白细胞、血小板有轻度下降，随后白细胞及血小板开始恢复。放疗前后白细胞、血小板数比较，差异有统计学意义(p &lt; 0.05)。治疗后1周复查白细胞及血小板均有不同程度的下降，治疗第3周白细胞、血小板明显上升，治疗后12周血小板开始有下降趋势。对照红细胞及血红蛋白放疗前后比较，差异无统计学意义(p &gt; 0.05)。治疗后门静脉主干，脾静脉，脾指数均有不同程度缩小，差异有统计学意义(p &lt; 0.05)。结论：原发性肝癌导致的脾功能亢进予低剂量姑息性放射治疗可以使脾脏体积和血供减小，白细胞、血小板上升，有效的缓解患者症状。此方法是一种安全、有效的治疗方式，值得临床推广应用。</p><p>关键词 :放射治疗，原发性肝癌，脾功能亢进</p><disp-formula id="hanspub.21846-formula43"><graphic xlink:href="http://html.hanspub.org/file/2-2530063x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2017 by authors and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="http://image.hanspub.org:8080\Html/htmlimages\1-2890033x\e70a10f1-7c93-45ea-9603-062237856e4b.png" /><img src="http://image.hanspub.org:8080\Html\htmlimages\1-2890033x\e898c85e-ffc4-45c9-b817-14224a4d6960.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>中国为肝细胞性肝癌(hepatocellular carcinoma, HCC)高发国家，是我国恶性肿瘤死亡原因的第2位。在我国肝癌合并肝硬化者占85%~90%，其中乙型及丙型肝炎后所导致的肝硬化占80%以上 [<xref ref-type="bibr" rid="hanspub.21846-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.21846-ref2">2</xref>] ，其中90%患者HBsAg或其它抗原抗体阳性 [<xref ref-type="bibr" rid="hanspub.21846-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.21846-ref4">4</xref>] 。肝硬化导致的门脉压力升高往往会使脾脏血液的回流受阻，致使脾脏淤血肿大，继而发生脾功能亢进(hypersplenism) [<xref ref-type="bibr" rid="hanspub.21846-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.21846-ref6">6</xref>] 。脾亢致血细胞减少又易致出血和感染的发生 [<xref ref-type="bibr" rid="hanspub.21846-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.21846-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.21846-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.21846-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.21846-ref11">11</xref>] 。肝硬化门静脉压力升高引起脾脏充血性肿大及脾脏纤维化进而脾功能亢进，发生率达50%~64% [<xref ref-type="bibr" rid="hanspub.21846-ref12">12</xref>] 。临床上通常采用脾切除或脾动脉栓塞来治疗，但仍有一部分人不能或不愿意接受手术及栓塞治疗。从2008年至2013年，我院选择肝癌合并脾亢患者28例，实施低剂量姑息性放射治疗肝硬化脾脏功能亢进，取得了较好的效果。通过放射治疗使脾亢得以改善，减少了手术所导致的创伤，又可以避免了手术切脾后的“无脾状态”，有利于维持机体免疫平衡，减少了免疫功能下降而感染</p></sec><sec id="s4"><title>2. 临床资料</title><p>基线特征从2008年至2013年，选择包头市中心医院肝癌合并脾亢患者28例，其中男性19例，女性9例，年龄45~72岁，中位年龄56岁(详见表1)。</p><p>治疗设备6-MV直线加速器(Siemens公司PRIMUS)、三维治疗计划系统(飞利浦Pinnacle 3治疗计划系统)、CT定位机(Siemens公司Sensation Open定位CT)、体架和热塑体膜。彩超( ALOKA Prosound 4彩色多普勒超声诊断仪)。</p><p>1) 入组标准</p><p>肝癌合并脾功能亢进患者，无肝功能衰竭。血常规指标：血白细胞(WBC)计数低于4.0 &#215; 10<sup>9</sup>/L，血小板(PI)计数低于50 &#215; 10<sup>9</sup>/L。B超、CT检查符合脾功能亢进的诊断。所有患者均采用2002年UICC分期标准进行分期。</p><p>2) 排除标准</p><p>肝功能衰竭；肝癌出现多脏器转移，且预计生存期 &lt; 3月；患者和家属拒绝进行放射治疗。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Clinical characteristi</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >入组人数</th><th align="center" valign="middle" >28</th></tr></thead><tr><td align="center" valign="middle" >年龄(中位年龄)</td><td align="center" valign="middle" >45~72 (56)</td></tr><tr><td align="center" valign="middle" >性别(%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >男性</td><td align="center" valign="middle" >11 (67.8)</td></tr><tr><td align="center" valign="middle" >女性</td><td align="center" valign="middle" >9 (32.1)</td></tr><tr><td align="center" valign="middle" >初始治疗(%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >手术</td><td align="center" valign="middle" >3 (10.7)</td></tr><tr><td align="center" valign="middle" >肝动脉栓塞介入</td><td align="center" valign="middle" >9 (64.3)</td></tr><tr><td align="center" valign="middle" >微波或射频消融介入</td><td align="center" valign="middle" >4 (14.3)</td></tr><tr><td align="center" valign="middle" >既往未接受治疗</td><td align="center" valign="middle" >3 (10.7)</td></tr><tr><td align="center" valign="middle" >Child分级</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >A级(%)</td><td align="center" valign="middle" >5 (17.9)</td></tr><tr><td align="center" valign="middle" >B级(%)</td><td align="center" valign="middle" >16 (57.1)</td></tr><tr><td align="center" valign="middle" >C级(%)</td><td align="center" valign="middle" >7 (25)</td></tr><tr><td align="center" valign="middle" >TNM分期</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >I期(%)</td><td align="center" valign="middle" >0 (0)</td></tr><tr><td align="center" valign="middle" >II期(%)</td><td align="center" valign="middle" >0 (0)</td></tr><tr><td align="center" valign="middle" >III期(%)</td><td align="center" valign="middle" >4 (14.3)</td></tr><tr><td align="center" valign="middle" >IV期(%)</td><td align="center" valign="middle" >24 (85.7)</td></tr></tbody></table></table-wrap><p>表1. 临床特征</p><p>评价指标采用血常规评价外周血中：红细胞，白细胞。血小板，血红蛋白等指标。脾的大小采用脾指数进行评价，彩超(探头频率3.5~5.0 MHz) 测量门静脉主干(main portal vein, MPV)和脾静脉(spleen vein, SPV)，脾长径、厚度及脾门至下缘角距离, 并计算出脾指数 [<xref ref-type="bibr" rid="hanspub.21846-ref13">13</xref>] (SPI, SPI = 脾厚度 * 脾门至下缘角距离)。在治疗前，治疗开始后1周测1次血常规及超声，放疗结束后1个月监测1次，随访12周。</p><p>放疗计划治疗前行脾脏CT模拟定位确定脾脏的大小，并进行放射治疗计划制作。靶区定义：CTV: CT所示脾脏实际范围，PTV = CTV + 1.0 cm。PTV至少95% 等剂量曲线包括95% 靶区。危及器官(organ of risk, OAR)：肝脏V10 &lt; 30%，脊髓 &lt; 2000 cGy，肾脏V10 &lt; 30%。根据患者一般情况分割剂量为150~250 cGy/次，5次/周，总剂量1000~2500 cGy，治疗4周后复查血常规，血象恢复未超过50%及脾脏缩小不明显(脾指数下降小于10%)根据脾脏大小适当调整剂量，再予以500 cGY/100 cGY/5 Fx/5 d放疗。放疗不良反应观察及检测和预防，放疗后每周监测血常规变化情况，白细胞及血小板下降程度，每周监测肝脏及肾脏损伤情况。发生不良反映及时处理，严重不良反映发生时立即停止放疗(表2)。</p><p>统计学处理计量资料用均数&#177;标准差(X &#177; SD)表示。采用SPSS 14.0软件进行方差分析，t检验，P &lt; 0.05表示差异有显著性。</p></sec><sec id="s5"><title>3. 结果</title><p>血常规变化情况在治疗刚才开始1周白细胞、血小板有轻度下降，脾脏开始缩小后白细胞及血小板开始恢复。放疗前后白细胞、血小板数比较差异有统计学意义p &lt; 0.05。28例患者治疗后1周复查白细胞及血小板均有不同程度的下降，治疗第3周白细胞，血小板明显上升，治疗后12周血小板开始有下降趋势。患者红细胞及血红蛋白放疗前后比较差异无统计学意义p &gt; 0.05 (详见表3)。</p><p>脾脏缩小情况28例患者在治疗过程中密切监测脾脏的大小和脾静脉，门静脉宽度，各项指标治疗前后变化情况见表3。结果显示治疗后门静脉主干，脾静脉，脾指数均有不同程度缩小，差异有统计学意义p &lt; 0.05。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Radiotherapy regimen</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >入组人数</th><th align="center" valign="middle" >28</th></tr></thead><tr><td align="center" valign="middle" >治疗次数(n)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >每日1次</td><td align="center" valign="middle" >22</td></tr><tr><td align="center" valign="middle" >隔日1次</td><td align="center" valign="middle" >6</td></tr><tr><td align="center" valign="middle" >照射野设野方式</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >前后对穿(AP-PA)</td><td align="center" valign="middle" >7</td></tr><tr><td align="center" valign="middle" >单前野</td><td align="center" valign="middle" >2</td></tr><tr><td align="center" valign="middle" >三野适形</td><td align="center" valign="middle" >19</td></tr><tr><td align="center" valign="middle" >照射野面积cm<sup>2</sup> (中位面积)</td><td align="center" valign="middle" >100~385 (234.5)</td></tr><tr><td align="center" valign="middle" >照射野缩小cm<sup>2</sup> (中位缩小面积)</td><td align="center" valign="middle" >0~134 (14.6)</td></tr><tr><td align="center" valign="middle" >照射野缩小比率% (中位比率)</td><td align="center" valign="middle" >0~25.4 (14.6)</td></tr><tr><td align="center" valign="middle" >单次分割放射剂量cGy (中位剂量)</td><td align="center" valign="middle" >100~250 (150)</td></tr><tr><td align="center" valign="middle" >总放射剂量cGy (中位剂量)</td><td align="center" valign="middle" >1000~2500 (1500)</td></tr><tr><td align="center" valign="middle" >无病生存期周(PFS)</td><td align="center" valign="middle" >2~32 (16)</td></tr><tr><td align="center" valign="middle" >总生存期周</td><td align="center" valign="middle" >3~51 (25)</td></tr><tr><td align="center" valign="middle" >未能完成治疗(%)</td><td align="center" valign="middle" >2 (0.70)</td></tr></tbody></table></table-wrap><p>表2. 放射治疗方案</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> The changes of indexes before and after treatment (x &#177; s</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >治疗前</th><th align="center" valign="middle" >治疗第2周</th><th align="center" valign="middle" >治疗第4周</th><th align="center" valign="middle" >治疗后12周</th><th align="center" valign="middle" >p</th></tr></thead><tr><td align="center" valign="middle" >白细胞 &#215; 10<sup>9</sup></td><td align="center" valign="middle" >3.85 &#177; 1.41</td><td align="center" valign="middle" >3.61 &#177; 0.75</td><td align="center" valign="middle" >4.32 &#177; 1.54</td><td align="center" valign="middle" >4.87 &#177; 1.21</td><td align="center" valign="middle" >p &gt; 0.05</td></tr><tr><td align="center" valign="middle" >血小板 &#215; 10<sup>9</sup></td><td align="center" valign="middle" >31.5 &#177; 15.4</td><td align="center" valign="middle" >18.5 &#177; 9.23</td><td align="center" valign="middle" >71 &#177; 12.2</td><td align="center" valign="middle" >65 &#177; 20.6</td><td align="center" valign="middle" >p &lt; 0.05</td></tr><tr><td align="center" valign="middle" >红细胞 &#215; 10<sup>12</sup></td><td align="center" valign="middle" >2.52 &#177; 0.55</td><td align="center" valign="middle" >2.73 &#177; 0.55</td><td align="center" valign="middle" >3.15 &#177; 2.01</td><td align="center" valign="middle" >3.31 &#177; 1.3</td><td align="center" valign="middle" >p &gt; 0.05</td></tr><tr><td align="center" valign="middle" >血红蛋白g/L</td><td align="center" valign="middle" >87.2 &#177; 15.3</td><td align="center" valign="middle" >85.1 &#177; 10.6</td><td align="center" valign="middle" >90.2 &#177; 11.3</td><td align="center" valign="middle" >93.1 &#177; 20.5</td><td align="center" valign="middle" >p &lt; 0.05</td></tr><tr><td align="center" valign="middle" >肋下脾脏长度(cm)</td><td align="center" valign="middle" >9.24 &#177; 2.12</td><td align="center" valign="middle" >8.85 &#177; 3.89</td><td align="center" valign="middle" >7.96 &#177; 3.87</td><td align="center" valign="middle" >7.58 &#177; 2.44</td><td align="center" valign="middle" >p &lt; 0.05</td></tr><tr><td align="center" valign="middle" >门静脉宽度(mm)</td><td align="center" valign="middle" >11.62 &#177; 3.25</td><td align="center" valign="middle" >11.25 &#177; 2.28</td><td align="center" valign="middle" >9.58 &#177; 1.63</td><td align="center" valign="middle" >7.63 &#177; 1.51</td><td align="center" valign="middle" >p &lt; 0.05</td></tr><tr><td align="center" valign="middle" >脾静脉宽度(mm)</td><td align="center" valign="middle" >6.25 &#177; 0.41</td><td align="center" valign="middle" >6.28 &#177; 0.35</td><td align="center" valign="middle" >5.45 &#177; 0.41</td><td align="center" valign="middle" >4.98 &#177; 0.37</td><td align="center" valign="middle" >p &lt; 0.05</td></tr><tr><td align="center" valign="middle" >脾指数cm<sup>3 </sup></td><td align="center" valign="middle" >194.21 &#177; 64.85</td><td align="center" valign="middle" >186.52 &#177; 52.86</td><td align="center" valign="middle" >164.36 &#177; 35.52</td><td align="center" valign="middle" >152.45 &#177; 51.32</td><td align="center" valign="middle" >p &lt; 0.05</td></tr></tbody></table></table-wrap><p>表3. 治疗前后各项指标的变化情况(x &#177; s)</p><p>28例病人均完成预定治疗。因对肝脏的受量进行严格控制，所有患者未发现肝脏损害。6例病人出现消化道反应，主要表现为轻微恶心，均未出现呕吐，食欲下降，改分割方式为隔日一次放疗后症状缓解。</p></sec><sec id="s6"><title>4. 讨论</title><p>脾脏的放射治疗最早开始于1个世纪以前，用于1位当时已经没有任何有效治疗方式的慢性白血病患者，经过治疗后，病人脾的体积缩小，血象恢复，取得了良好的效果。由于肝硬化患者肝储备功能不佳，行过于激进的治疗手段，有可能导致肝功能的进一步恶化，脾脏的放射治疗对于难以接受化疗，手术，介入栓塞或消融等创伤较大治疗手段的姑息性治疗，对脾功能亢进，脾区疼痛和不适等均有一定的效果。</p><p>原发性肝癌患者约85%~90%合并有肝硬化，肝硬化继发脾功能亢进，因脾索纤维组织增生, 使脾脏体积增大弹性变小，血流阻力增加，导致血小板，白细胞的减少，可以引起凝血功能异常、免疫功能低下等相关的并发症，严重影响针对肝癌的手术和栓塞化疗等治疗。要提高肝癌的治疗效果，控制脾功能亢进等相关的并发症就十分重要。本研究采用的三维适形放疗就有定位准确、剂量集中、可以最大程度地增加肿瘤的局部控制率、降低周围正常组织的放射并发症发生率的优点，所以正常组织受照射剂量较小，几乎无不良反应，与其他技术相比，最大的优点是不造成患者的血流动力学改变，对人体损伤较少，能够充分的保护病人的体质，提高患者的生活质量，对于那些有手术禁忌症、不愿手术或常规治疗手段治疗失败的患者提供了另外一种治疗选择。</p><p>由于目前进行脾脏放射治疗的经验较少 [<xref ref-type="bibr" rid="hanspub.21846-ref14">14</xref>] ，所以脾脏放射治疗的放疗剂量，分割模式目前没有成熟的经验；同时对放射线作用于脾脏所产生的放射生物效应也缺乏清晰的认识。 [<xref ref-type="bibr" rid="hanspub.21846-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.21846-ref16">16</xref>] 放射治疗可以控制脾内免疫组织(脾小体、动脉周围淋巴鞘、边缘带等)增生，使脾脏缩小，减少脾脏对血细胞的破坏，促使血细胞的恢复。目前认为脾脏经照射后会引淋巴细胞的死亡，淋巴细胞亚群和细胞因子激活所导致的免疫功能变化 [<xref ref-type="bibr" rid="hanspub.21846-ref17">17</xref>] [<xref ref-type="bibr" rid="hanspub.21846-ref18">18</xref>] 。从而进一步引起组织细胞的变性、坏死, 其纤维化修复导致脾脏功能减退甚至消失, 从而达到类似切除脾脏的效果。通过放射治疗抑制脾功能, 使白细胞、血小板在脾内的破坏减少, 从而使其在血液中逐渐增高, 恢复至正常, 减少了感染和出血的危险。</p><p>在本研究中放疗第1周复查脾脏缩小不明显，这可能是导致放疗早期白细胞及血小板不升高反而下降的原因，早期脾脏体积不减小，同时由于放疗对血细胞的破坏存在，导致了白细胞和血小板下降。放疗后期脾脏开始缩小时白细胞和血小板开始上升。Kost等 [<xref ref-type="bibr" rid="hanspub.21846-ref19">19</xref>] 在进行脾脏放疗时，左肾的V20 &gt; 40%，在本研究中，左肾的最大剂量位18.7 Gy，平均剂量为9 Gy，显著的降低了正常组织的受量，减少周围正常组织的并发症。</p><p>原发性肝癌虽然是放射治疗敏感的恶性肿瘤，但由于脾功能亢进的直接原因是由于肝硬化所导致的门脉高压，而不是恶性肿瘤的肝脏浸润，所以本研究采取了相对比较大的分割剂量，单次分割剂量为100~250 cGy，中位剂量150 cGy，其中100 cGy (14.6%) 和200 cGy (60.7%)，累积剂量1000~2500 cGy，中位剂量1500 cGy。放疗后白细胞，血小板，门静脉主干，脾静脉和脾指数等各项指标均有明显改善，治疗安全有效，由于所选取的患者均为晚期患者，所以患者的生存期相对较短，单脾脏放射治疗有效的减轻患者的症状，提高了患者生活质量。</p></sec><sec id="s7"><title>5. 结论</title><p>原发性肝癌导致的脾功能亢进予低剂量姑息性放射治疗可以使脾脏体积和血供可减小，白细胞，血小板上升，有效的缓解患者症状。是一种安全、有效的治疗方式，值得临床推广应用。对于一般状况差或拒绝接受化疗，手术，介入栓塞或消融等创伤较大治疗的患者，可以优先考虑进行脾脏的放射治疗。</p></sec><sec id="s8"><title>文章引用</title><p>王树斌,袁 飞,武 云. 原发性肝癌合并脾功能亢进低剂量姑息性放射治疗的临床研究Clinical Study of Low Dose Palliative Radiotherapy for Hepatocellular Carcinoma Complicated with Hypersplenism[J]. 亚洲肿瘤科病例研究, 2017, 06(04): 26-32. http://dx.doi.org/10.12677/ACRPO.2017.64005</p></sec><sec id="s9"><title>参考文献 (References)</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.21846-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, Q., Ji, X.W., Hou, X.M., et al. (2014) Effect of Functional Nuclear Factor KappaB Genetic Polymorphisms on Hepatitis B virus Persistence and Their Interactions with Viral Mutations on the Risk of Hepatocellular Carcinoma. Annals of Oncology, 25, 2413-2419. &lt;br&gt;https://doi.org/10.1093/annonc/mdu451</mixed-citation></ref><ref id="hanspub.21846-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">中华医学会肝病分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015年更新版) [J]. 临床肝胆病杂志, 2015, 31(12): 1941-1960.</mixed-citation></ref><ref id="hanspub.21846-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">吴孟超, 陈汉, 沈锋. 原发性肝癌的外科治疗[J]. 中华外科杂志, 2001, 39(1): 25-28.</mixed-citation></ref><ref id="hanspub.21846-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Wang, F.S., Fan, J.G., Zhang, Z., et al. (2014) The Global Burden of Liver Disease: The Major Impact of China. Hepatology, 60, 2099-2108.</mixed-citation></ref><ref id="hanspub.21846-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Liangpunsakul, S., Ulmer, B.J. and Chalasani, N. (2003) Predictors and Implications of Severe Hypersplenism in Patients with Cirrhosis. The American Journal of the Medical Sciences, 326, 111-116.  
&lt;br&gt;https://doi.org/10.1097/00000441-200309000-00001</mixed-citation></ref><ref id="hanspub.21846-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Del Guercio, L.R.M., Hodgson, W.J.B., Morgan, J.C., et al. (1984) Splenic Artery and Coronary Vein Occlusion for Bleeding Esophageal Varices. World Journal of Surgery, 8, 680-687. &lt;br&gt;https://doi.org/10.1007/BF01655763</mixed-citation></ref><ref id="hanspub.21846-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">慢性丙型肝炎抗病毒治疗专家委员会. 慢性丙型肝炎抗病毒治疗专家共识[J/CD]. 中华实验和临床感染病杂志:电子版, 2009, 3(3): 343-352.</mixed-citation></ref><ref id="hanspub.21846-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2010年版) [J]. 中华肝脏病杂志, 2011, 19(1): 13-24.</mixed-citation></ref><ref id="hanspub.21846-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">张效东, 余灵祥, 杨晓晋. 丙肝抗病毒治疗前脾切除纠正血小板减少症[J]. 肝胆外科杂志, 2009, 17(5): 348-351.</mixed-citation></ref><ref id="hanspub.21846-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Akahoshi, T., Tomikawa, M., Korenaga, D., et al. (2010) Laparoscopic Splenectomy with Peginterferon and Ribavirin therapy for Patients with Hepatitis C Virus Cirrhosis and Hypersplenism. Surgical Endoscopy, 24, 680-685.  
&lt;br&gt;https://doi.org/10.1007/s00464-009-0653-6</mixed-citation></ref><ref id="hanspub.21846-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Popa, M. and Vasilescu, C. (2010) Minimally Invasive Splenectomy for Thrombocytopenia Associated with Liver Cirrhosis. Chirurgia, 105, 15-20.</mixed-citation></ref><ref id="hanspub.21846-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">梁彦, 伊文静, 贾战生, 等. 肝硬化患者脾功能亢进治疗研究进展[J]. 临床肝胆病杂志, 2015, 31(11): 1924-1927.</mixed-citation></ref><ref id="hanspub.21846-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">谢冬英, 谢仕斌, 李勇忠, 等. 肝纤维化与门静脉、脾静脉直径、脾脏大小及血细胞计数的关系[J]. 中华消化杂志, 2000, 20(5): 308-310.</mixed-citation></ref><ref id="hanspub.21846-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Weinmann, M., Becker, G., Einsele, H., et al. (2001) Clinical Indications and Biological Mechanisms of Splenic Irradiation in Chronic Leukaemias and Myeloproliferative Disorders. Radiotherapy and Oncology, 58, 235-246.</mixed-citation></ref><ref id="hanspub.21846-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">McFarland, J.T., Kuzma, C., Millard, F.E., et al. (2003) Palliative Irradiation of the Spleen. American Journal of Clinical Oncology, 26, 178-183. &lt;br&gt;https://doi.org/10.1097/00000421-200304000-00016</mixed-citation></ref><ref id="hanspub.21846-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Jyothirmayi, R. and Coltart, S. (2005) An Audit of the Indications for and Techniques of Palliative Splenic Radiotherapy in the UK. Clinical Oncology, 17, 192-194.</mixed-citation></ref><ref id="hanspub.21846-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Gardner, K. and Weston, S.S. (2013) Wandering Spleen: A Mobile Target for Radiotherapy. American Journal of Hematology, 88, 528-529. &lt;br&gt;https://doi.org/10.1002/ajh.23425</mixed-citation></ref><ref id="hanspub.21846-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Kulkarni, H.R., Prasad, V., Schuchardt, C., et al. (2013) Is There a Correlation between Peptide Receptor Radionuclide Therapy-Associated Hematological Toxicity and Spleen Dose? Recent Results in Cancer Research, 194, 561-566.  
&lt;br&gt;https://doi.org/10.1007/978-3-642-27994-2_33</mixed-citation></ref><ref id="hanspub.21846-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Kost, S., Keinert, K., Endert, G., et al. (1998) Radiation Effects in the Left Kidney after Irradiation of the Spleen. Strahlentherapie und Onkologie, 175, 415-420.</mixed-citation></ref></ref-list></back></article>